Phosphorylation of the androgen receptor is associated with reduced survival in hormonerefractory prostate cancer patients by McCall, P. et al.
 
 
 
 
 
 
 
McCall, P. and Gemmell, L.K. and Mukherjee, R. and Bartlett, J.M.S. 
and Edwards, J. (2008) Phosphorylation of the androgen receptor is 
associated with reduced survival in hormone-refractory prostate cancer 
patients. British Journal of Cancer, 98 (6). pp. 1094-1101. ISSN 0007-
0920 
 
http://eprints.gla.ac.uk/7749/ 
 
Deposited on: 21 October 2009 
 
 
Enlighten – Research publications by members of the University of Glasgow 
http://eprints.gla.ac.uk 
 1 
Phosphorylation of the Androgen Receptor is associated with reduced survival in 
hormone refractory prostate cancer patients. 
Pamela McCall, Lisa K Gemmell, Rono Mukherjee, John M.S. Bartlett, and Joanne 
Edwards, 
Section of Surgery, Division of Cancer Sciences and Molecular Pathology, Glasgow 
Royal Infirmary, Glasgow. 
 
Corresponding author        
Dr Joanne Edwards 
Section of  Surgery 
Division of Cancer Sciences and Molecular Pathology  
Level 2, Queen Elizabeth Building 
Glasgow Royal Infirmary 
Glasgow 
G31 2ER 
Tel 44 141 211 5441 
Fax 44 141 552 3229 
e-mail je10b@clinmed.gla.ac.uk 
Short title: Phosphorylation of androgen receptor in prostate cancer 
 
 
 2 
Cell line studies demonstrate that the PI3K/Akt pathway is up-regulated in hormone 
refractory prostate cancer and can result in phosphorylation of the androgen receptor 
(AR).  The current study therefore aims to establish if this has relevance to the 
development of clinical hormone refractory prostate cancer. 
Immunohistochemistry was employed to investigate the expression and 
phosphorylation status of Akt and AR in matched hormone sensitive and refractory 
prostate cancer tumours from 68 patients.  
In the hormone refractory tissue only phosphorylated AR (pAR) was associated with 
shorter time to death from relapse (p=0.003).  However when an increase in 
expression in the transition from hormone sensitive to hormone refractory prostate 
cancer was investigated an increase in expression of PI3K was associated with 
decreased time to biochemical relapse (p=0.014) and an increase in expression of 
pAkt473 and pAR210 were associated with decreased disease specific survival 
(p=0.0019, and p=0.0015, respectively).  Protein expression of pAkt473 and pAR210 
also strongly correlated (p<0.001 c.c. 0.711) in the hormone refractory prostate 
tumours. 
These results provide evidence using clinical specimens, that up-regulation of the 
PI3K/Akt pathway is associated with phosphorylation of the AR during development 
of hormone refractory prostate cancer, suggesting this pathway could be a potential 
therapeutic target. 
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Introduction 
Prostate cancer is an increasing heath care problem, 1 in 6 UK men are diagnosed with 
this disease which ranks 2nd behind lung cancer as a cause of male cancer specific 
mortality (Cancer Research UK web site, 2004).  Advanced prostate cancer treatment 
has relied on hormone deprivation therapy for the past 50 years.  Response rates are 
initially high (70-80%), however almost all patients relapse and develop hormone 
refractory prostate cancer, resulting in increased morbidity and death (Cleeve and 
Goad, 1995).  
Amplification of the androgen receptor (AR) may explain development of 
hormone refractory prostate cancer in 20-30% of patients (Edwards et al., 2001).  In 
vitro studies demonstrate that Akt/protein kinase B, phosphorylates AR at serine 
residues (Ser210 and Ser790) resulting in modulation of AR transcriptional activity (Lin 
et al., 2001;Lin et al., 2003) suggesting that AR phosphorylation might promote 
development of hormone refractory prostate cancer.  It has also been reported that 
activation of PI3K/Akt pathway can induce expression of AR at the protein and 
mRNA level, again suggesting that this pathway may be involved with hormone 
refractory disease (Yang et al., 2005).  Akt is a downstream member of the 
phosphatidylinositol 3-OH kinase (PI3K) cascade, which plays an important role in 
cell growth, death, adhesion and migration and is frequently activated in cancer cells 
(Lin et al., 2003).  Akt is activated when phosphorylated at threonine 308 and 
subsequently serine 473.  There are 3 members of the Akt family, Akt 1, 2 and 3, and 
evidence suggests that the 3 isoforms of Akt have different roles in the development 
of hormone resistant breast cancer either via interactions with the oestrogen receptor 
or via proteins involved in proliferation and apoptosis e.g. mTOR and BAD 
(Kirkegaard et al., 2005).  Akt may play a similar role in the development of hormone 
refractory prostate cancer (Liao et al., 2003).  Cell line studies demonstrate that low 
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passage LNCaP cells (hormone sensitive prostate cancer cells) have low basal Akt 
activity, possibly due to early stage prostate cancer relying on hormones for growth 
and survival.  However during hormone ablation or anti hormone treatment LNCaP 
cells undergo growth arrest and apoptosis, and Akt activity is up-regulated (more than 
20 fold higher), resulting in stimulation of cell growth, compensating for the effects of 
androgen withdrawal (Gao et al., 2003).  Data from these experiments suggests that 
Akt signals for cell growth and survival at low levels of androgen and therefore may 
promote development of hormone refractory prostate cancer (Ghosh et al., 2003;Lin et 
al., 2003). This is supported by a report that demonstrates that up-regulation of the 
PI3K cascade allows cells to grow in the presence of anti androgens and contributes to 
failure of endocrine therapy (Murillo et al., 2001).   
A recent review suggests that the PI3K/Akt pathway is a possible therapeutic 
target for treatment of prostate cancer (Pommery and Henichart, 2005).  Prostate 
tumours are reported to have significantly higher Akt expression than BPH (Liao et 
al., 2003) and only 10% of well-differentiated prostate tumours strongly express 
phosphorylated Akt compared to 92% of poorly differentiated tumours (Ayala et al., 
2003;Ghosh et al., 2003;Malik et al., 2002).  Akt-1 and Akt-2 expression in hormone 
sensitive tumours have been associated with shorter time to biochemical relapse, 
however no association was reported with the activated forms or with survival (Le 
Page et al., 2006).  However, to our knowledge this is the first study to conduct a 
comprehensive investigation into the changes that occur to multiple members of the 
pathway in the transition from clinical hormone sensitive to hormone refractory 
prostate cancer, and in particular to test if phosphorylation of AR is associated with 
patient outcome measures. 
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Materials and methods 
Patient  
Sixty eight patients with matched hormone sensitive and hormone refractory tumour 
pairs were retrospectively selected for analysis.  All tumours had patient identification 
removed, including block number and hospital number and were coded to make the 
database anonymous.  Ethical approval was obtained from the Multicentre Research 
Ethics Committee for Scotland (MREC/01/0/36) and Local Research and Ethical 
Committees.  Patients were only selected for analysis if they initially responded to 
hormone treatment (in the form of sub capsular bilateral orchidectomy or maximum 
androgen blockade) but subsequently relapsed (2 consecutive rises in PSA greater than 
10%) and had a pre and post hormone relapse tissue sample available for analysis.   
Immunohistochemistry 
All IHC was performed on 5 µm, archival formalin fixed, paraffin embedded prostate 
tumour sections on separate slides.  Immunohistochemistry for PI3K (p110 catalytic 
subunit), Akt1-3, phosphorylated Akt at threonine 473 (pAkt473), mTOR, 
phosphorylated mTOR at serine 2448 (mTOR2448) and phosphorylated AR at serine 
210 (pAR210) were performed as follows: Antigen retrieval was performed using heat 
treatment under pressure in a Tris EDTA Buffer (5mM Trizma Base, 1mM EDTA, pH 
8: Akt 1-3 and pAR210) or citrate buffer (PI3K, and mTOR) for 5 min or by heating to 
96ºC for 20 minutes in citrate buffer (pAkt308, pAkt308 and pmTOR2448). Non-specific 
background staining was blocked using either 2.5% horse serum in TBS for 20 
minutes (PI3K, pAR210), in 1% casein for 10 min (Akt1-3, mTOR, pmTOR2448) or in 
Serum Free Block (Dako A/S) for 10 min (pAkt473). PI3K (Cell Signalling 
Technology, Beverly, USA), Akt1-3 (Santa Cruz Biotechnology Inc, Santa Cruz, 
USA), pAkt473 (Cell Signalling Technology), mTOR (Santa Cruz Biotechnology Inc), 
pmTOR2448 (Cell Signalling Technology) and pAR210 (Imgenex, San Diego, USA) 
antibodies were used at the following concentrations (1µg/ml, 1µg/ml, 2µg/ml, 
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2µg/ml, 4µg/ml, 5µg/ml, 2µg/ml and 50µg/ml ).  pAR210 was incubated for 1 hour at 
25°C and all other antibodies were incubated overnight at 4°C.  For the mTOR 
antibody only, incubation with rabbit anti-goat antibody (Dako A/S) (1:4000) for 1 h 
at room temperature was also required. Staining for PI3K, pAkt308, pAkt473, mTOR 
and pmTOR2448 was developed using EnVision plus kit (Dako A/S) and staining for 
Akt 1-3 and pAR210 was developed using LSAB kit (Dako A/S) and 3,3-
diaminobenxidine teretrahydrochloride (DAB; Vector Laboratories). Nuclei were 
counterstained with haematoxylin before mounting.  A positive and negative control 
was included in each IHC run, negative controls were incubated with an isotype 
matched control antibody at a concentration of 1mg/ml.  Positive control slides were 
breast tissue known to express PI3K, Akt and mTor, BPH tissue known to express AR 
and MCF-7 and LNCaP cell pellets.  Antibody specificity was confirmed by western 
blotting.  In addition, phosphorylated antibodies were confirmed to detect only the 
phosphorylated forms using Calf Intestinal Alkaline Phosphatase to destroy 
phosphorylated proteins. Two identical slides had IHC performed on them, the only 
difference being that one was previously treated with Calf Intestinal Alkaline 
Phosphatase, the untreated slide expressed the phosphorylate protein and the treated 
slide did not, this technique confirms that the antibody is only detecting the 
phosphorylated form of the protein and not the unphosphorylated form.  
Tissue staining intensity was scored blind by 2 independent observers using a 
weighted histoscore method (Fraser et al., 2003) also known as the Hscore system 
(McCarty, Jr. et al., 1986). Histoscores were calculated from the sum of (1 x % cells 
staining weakly positive) + (2 x % cell staining moderately positive) + (3 x % cells 
staining strongly positive) with a maximum of 300. The inter-class correlation 
coefficient (ICCC) for each protein was calculated to confirm consistency between 
observers and the mean of the two observers’ scores were used for analysis.  Changes 
in staining between pre and post hormone refractory cases were defined as an increase 
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or decrease out with the 95% confidence interval for the difference in inter-observer 
variation i.e. the mean difference between the histoscores that each observer assigns 
for protein expression plus 2 standard deviations.  Change in expression of PI3K, 
Akt1, Akt2, Akt3, mTOR, pmTOR2448 and pAR210 are shown in table 1.   
 
Statistical Analysis 
Interclass correlation coefficients were used to confirm consistency between 
observers. Protein expression data were not normally distributed and are shown as 
median and inter quartile ranges.  Wilcoxon Signed Rank Tests were used to compare 
expression between pre and post hormone refractory tumours. Survival analyses were 
conducted using Kaplan-Meier method and curves were compared with the log-rank 
test.  Hazard ratios (HR) were calculated using Cox Regression analysis.  Correlations 
between members of the pathway were performed using a Spearmans rank test. 
 
Results 
Patients 
A total of 68 prostate cancer patients (diagnosed between 1984-2000) were included 
in this study with matched hormone sensitive (hormone sensitive tissue was obtained 
from 26 patients by TRUS guided biopsy and the remaining 42 by TURP) and 
refractory prostate tumours (all obtained by TURP) available for analysis (136 
tumours in total).  Patients in this cohort were diagnosed with locally advanced (50) or 
metastatic prostate cancer (18) and subsequently received surgery and androgen 
deprivation therapy (26 sub capsular bilateral orchidectomy, 44 GnRH analogue, 2 
had both).  Forty five of the 68 patients also received anti androgen therapy and this 
included all those who received GnRH analogues.  At initial diagnosis the median age 
was 70 (66-74) years and 26% of patients had metastatic disease.  The median time to 
biochemical relapse was 2.32 (1.48-4.00) years and the percentage of patients with 
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metastatic disease had increased to 57%.  Sixty-one patients (89.7%) died during 
follow-up and median survival for these patients was 4.34 (2.94-6.63).  Seven patients 
were alive at last follow-up, the median time of follow-up for all 68 patients was 4.34 
(2.86-6.74) years.   
 
 
Protein expression patterns 
 
Akt 1, pAkt473 and pmTOR2448 protein expression was observed in the cell membrane, 
cytoplasm or nucleus.  mTOR expression was observed at the membrane and 
cytoplasm and PI3K, Akt2 and Akt3 expression was observed only in the cytoplasm.  
Nuclear expression was observed for pAR210 , (figure 1, table 1). In order to assess the 
level of agreement between observers, interclass correlation coefficients (ICCC) were 
calculated for each antibody at each location using SPSS, all ICCC values in this 
study were greater  >0.7 (which is classed as excellent) (table 1). 
Protein expression levels and changes in protein expression. 
The median expression levels for all proteins investigated were calculated for 
hormone sensitive and hormone refractory tumours (table 1).  The Wilcoxon Signed 
Rank test was used to compare expression levels in the hormone sensitive tumours 
compared to hormone refractory tumours.  Using this method only pAR210 
significantly increased with the development of hormone refractory disease.  The 
median expression of pAR210 in hormone sensitive tumours was 35(0-85) increasing 
to 103(50-169) in hormone refractory tumours (p<0.0001) (table 1).  This 
demonstrates an increase in AR phosphorylation at the Akt consensus site in the 
transition from hormone sensitive to hormone refractory disease.   
The nature of our cohort however (matched hormone sensitive and hormone 
refractory tumours for each patient) allowed us to establish if there was a change in 
protein expression levels in the transition from hormone sensitive to hormone 
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refractory disease for each individual patient.  By examining the change in protein 
expression for each patient we were able to create sub groups of patients whose 
tumours exhibited either a fall or rise in protein expression for all proteins investigated 
(table 1).  Using this technique it was observed that 42% of patients investigated in 
this study had an increase in pAR210 expression in the transition from hormone 
sensitive to hormone refractory disease (figure 1). 
Are protein expression levels in hormone sensitive or hormone refractory tumours 
associated with relapse or survival? 
When expression levels of each protein investigated in the hormone sensitive tumours 
were divided into to high or low expression (levels above or below the median) none 
of the proteins investigated were associated with time to relapse or disease specific 
survival.  The histoscores used as a cut off for each analysis was the median 
histoscore, the median histoscore for each protein investigated is given in table 1. 
When expression levels of each protein investigated in the hormone refractory 
tumours were divided into to high or low expression (levels above or below the 
median) only pAR210 was associated with quicker time to death from relapse (figure 
2a, p=0.003, HR 2.85 (95% C.I., 1.38-5.87)) and quicker disease specific survival 
(figure 2b, p=0.0136, HR 2.33 (95% C.I., 1.16-4.66).  Median survival from time of 
relapse for those patients with tumours that expressed low levels of pAR210 was 3.42 
(IQR, 2.82-4.02) years compared to 1.40 (IQR, 0.85-1.95) years  for those who had 
tumours that expressed high levels of pAR210 and the median disease specific survival 
for those patients with tumours that expressed low levels of pAR210 was 8.57 (IQR, 
5.41-11.73) years compared to 5.82 (IQR, 3.18-8.46) years for those who had tumours 
that expressed high levels of pAR210.  This represents a survival difference of almost 3 
years for patients expressing high levels of pAR210 in their hormone refractory tumour. 
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Are changes in protein expression in the transition from hormone sensitive to 
hormone refractory disease associated with relapse or survival? 
When expression levels in hormone sensitive or hormone refractory tumours were 
used to investigate a link between activation of the PI3K pathway and development of 
hormone refractory disease, only AR phosphorylated at the Akt consensus site was 
associated with survival.  However due to the nature of the current cohort we were 
also able to investigate if those patients whose tumours exhibit an increase or rise in 
expression of members of the pathway in the transition from hormone sensitive to 
hormone refractory disease were more likely to relapse or die quicker.  The cut-off 
histoscore selected to separate subgroups of patients is displayed in table 1.  Using this 
method an increase in PI3K (Figure 3a, p=0.014, HR 2.11 (95% C.I., 1.14-3.91)) was 
associated with quicker time to relapse.  The median time to relapse for those patients 
whose tumours have a decrease or no change in PI3K expression was 2.57 (IQR, 1.74-
3.40) years compared to 1.36 (IQR, 1.20-2.72) years for those patients whose tumours 
had an increase in PI3K expression. 
A rise in pAR210 (Figure 3b, p<0.0001, HR 4.18 (95% C.I., 1.99-8.74)) was 
associated with quicker time to death from relapse, the median survival from 
biochemical relapse for those patients whose tumours had a decrease or no change in 
pAR210 expression was 3.46 (IQR, 1.39-5.53) years compare to 1.25 (IQR, 0.83-1.67) 
years for those patients whose tumours had an increase in pAR210 expression.   
A rise in pAkt473 (Figure 3c, p=0.0019, HR 2.89(95% C.I., 1.43-5.8)) and 
pAR210 (Figure 3d, p=0.0015, HR 2.86 (95% C.I., 1.45-5.67)) were associated with 
shorter disease specific survival. The median survival from diagnosis for those 
patients whose tumours had no change or decrease in pAkt473 was 6.68 (IQR, 6.22-
7.14) years compare to 4.15 (IQR, 2.65-65) years for those patients whose tumours 
had an increase in pAkt473expression and the median survival from diagnosis for those 
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patients whose tumours had a decrease or no change in expression of pAR210 was 6.95 
(IQR, 4.07-9.83) years compare to 4.36 (IQR, 1.67-7.10) years for those patients 
whose tumours had an increase in pAR210expression.  Therefore an increase in 
expression in the transition from hormone sensitive to hormone refractory disease of 
phosphorylated members of this pathway was associated with a reduction in median 
survival of 2.5-3 years. 
Correlations between active members of the pathway 
In hormone sensitive tumours expression levels of the phosphorylated proteins did not 
correlate, no correlation was made between Akt activation and AR phosphorylation 
(Figure 4a).  However in the hormone refractory tumours pAkt473 correlated with 
pAR210 (rs=0.711, p<0.001) (Figure 4b) and pmTOR2448 (rs.=0.489, p=0.003).   Table 
2 shows the individual histoscores for pAkt and PI3K in patients with and without 
pAR210 increases, no changes in median expression levels was observed between the 
groups. 
Discussion 
Cell line studies demonstrate that the PI3K cascade may influence the development of 
hormone refractory prostate cancer (HRPC), suggesting this pathway may provide a 
novel therapeutic target for prostate cancer.  However in order to translate this into the 
clinic we are required to provide evidence that this pathway is up-regulated in the 
development of clinical hormone refractory prostate cancer and also identify what 
proteins would make the best targets and most effectively identify patients suitable for 
therapy.   
It is well established in the literature that there is a link between Akt activation and 
development of hormone refractory prostate cancer.  Cell line work demonstrates that 
Akt activity increases during androgen ablation to stimulate cell growth and survival 
when androgen reliance is weaker and therefore promote development of hormone 
refractory prostate cancer (Gao et al., 2003;Ghosh et al., 2003;Lin et al., 2003).  Work 
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using human prostate tissue confirms that pAkt473 is expressed in PIN and invasive 
prostate cancer and staining intensity positively correlated with PSA levels and 
Gleason (Altomare and Testa, 2005;Ghosh et al., 2003;Majumder and Sellers, 2005).  
In addition a large study of 640 radical prostatectomy specimens demonstrated that 
high levels of phosphorylated Akt was predictive of biochemical recurrence (Ayala et 
al., 2003).  Although in our current cohort we did not observe a significant association 
with phosphorylated Akt 473 and biochemical recurrence (pAkt473 p= 0.151, results 
not shown), the Kaplan Meier curves did separate and the difference in the median 
time to biochemical recurrence in the 2 groups was 1.8 year compared to 2.4 years, 
suggesting that significance might have been meet if a larger cohort had been used.   
As the previous study was conducted on a cohort of 640 patient samples and our 
cohort was only contained 68 patients, we performed a power calculation to assess 
what cohort size would have been required, this calculation suggested that a cohort of 
200 patients would have been sufficient to reach significance.  It is therefore not 
surprising that a significant result was achieved on a cohort of 640 samples. However 
the design of our study was to mirror the cell line experiments and investigate if 
changes in protein expression of members of the PI3K/Akt cascade were involved in 
the transition from hormone sensitive disease to hormone refractory disease, therefore 
we felt that it was not necessary to increase that cohort size.  The strength of this study 
was the use of the paired samples, by doing so we observed that an increase in 
expression of multiple members of the pathway was linked to time to recurrence and 
disease specific survival.  In addition, if primary tumours only had been used we 
would not have observed that pAR210 was linked to survival, as marked expression 
was only observe in hormone refractory tumours.  In the current study we observe that 
an increase pAkt473 expression, fully activated Akt and an increase in pAR210 was 
associated with decreased survival. Providing further evidence that activation of the 
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PI3K/Akt cascade is associated with development of hormone refractory prostate 
cancer. 
Cell line data suggests that phosphorylation of AR by Akt at serine 210 results 
in an increase in AR translational activity when androgen levels are low and in 
addition activated Akt, over a longer period, has been demonstrated to up-regulated 
AR expression in LNCaP cells (Manin et al., 2002;Yang et al., 2005).  The impact of 
both these actions of Akt on the AR will serve to increase the sensitivity of the AR to 
androgens, enabling transcription of AR regulated genes even when androgens levels 
are very low, similar to those experienced during chemical or surgical castration.  This 
therefore provides a mechanism for the development of hormone refractory prostate 
cancer.  In the current cohort, hormone refractory prostate tumours express 
significantly higher levels of pAR210 compared to hormone sensitive tumours, the 
median histoscore of refractory tumours is 103 histoscore units compared to 35 
histoscore units for sensitive tumours, p=<0.0001.  Approximately 42% of patients 
have an increase in pAR210 expression and these patients have a significantly shorter 
survival period than those with no increase in expression.  In addition, expression 
levels of pAR210 and AR strongly correlate with pAkt473 expression levels in the 
refractory tumours only, suggesting that it is only when androgen levels are low that 
this pathway is activated.  These results provide additional evidence that the PI3K/Akt 
pathway is up-regulated during development of hormone refractory prostate cancer, 
resulting in phosphorylation of the AR and sensitisation to circulating adrenal 
androgens.  Cell line studies demonstrate that this occurs in vitro, however the current 
data demonstrates for the first time that this may be one possible mechanism allowing 
development of hormone refractory prostate cancer in the clinical setting (Figure 5). 
The protein mTOR is also down stream of Akt and was also investigated in this 
study as it has previously been to hormone refractory prostate cancer (Bubley et al., 
2003). Akt can phosphorylate mTOR directly at threonine 2446 and serine 2448, but 
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can also activate mTOR indirectly via phosphorylation of TSC2 (Majumder and 
Sellers, 2005). In the current cohort pAkt473 expression correlates with pmTOR2448 
expression, however expression levels or changes in expression levels of pmTOR2448 
do not correlate with any clinical parameters in our cohort. This suggests that mTOR 
may not be involved in the development of hormone refractory prostate cancer.  This 
was surprising as stimulation of mTOR ultimately results in increase protein synthesis 
and enhances translation of proteins involved in growth control via turning off 4EBP 
and activating S6Kinase. Although Akt has been demonstrated to phosphorylate 
mTOR directly, the role of these phosphorylation sites remains unclear. 
Phosphorylation of mTOR by Akt at serine 2448 might not correlate with mTOR 
activation, therefore pmTOR2448 may not necessary be involved with the development 
of HRPC and a more appropriate marker of mTOR activation could be S6Kinase 
(Ruggero and Sonenberg, 2005).   
In summary, they current study demonstrates a role for the PI3K/Akt/AR 
pathway in the development of hormone refractory prostate cancer, however now that 
drugs are being developed to target specific components of pathways it is necessary to 
identify the proteins in the individual pathways that would make the most appropriate 
targets.  Results from the current study suggest that a larger portion of tumours would 
respond to drugs targeting Akt activation in contrast to PI3K or PTEN.  Methods 
currently being explored for inhibition of Akt activation include Akt antibodies, 
similar to humanized trastuxamab (Herceptin), ATP- competitive inhibitors and PDK1 
inhibitors (Cheng et al., 2005). In addition to Akt being the appropriate target for 
therapy, Akt in combination with pAR210 might be the appropriate marker for 
identifying patients most likely to respond drugs that target Akt activation.  
Phosphorylation of Akt and AR are clearly linked with decreased survival, those 
patients who have an increase in pAtk473 and/or pAR210  have median  overall survival 
period of 3.98 years compared to 6.68 years, this is a survival difference of  almost 3 
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years and approximately 50% of the patients in our study have an increase in pAkt473 
and/or pAR210 expression suggesting that the majority of patients likely to respond to 
Akt inhibition will be identified by these markers.  This study emphasises the need for 
a rational approach for new drug design and the progress already made in breast 
cancer demonstrates the effectiveness of such an approach.   
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Table 1  Histoscore variation and comparison of staining intensity for hormone 
sensitive and hormone refractory tumours. 
 HSPC 
(IQR) 
HRPC 
(IQR) 
P value ICCC Histoscore 
units 
Fallers Risers 
PI3Kc 100(58-140) 100(79-134) 0.875 0.85 60 23 23 
Akt1m 
Akt1c 
Akt1n 
0(0-11) 
75(20-100) 
0(0-18) 
0(0-90) 
70(0-90) 
0(0-0) 
0.798 
0.488 
0.110 
0.88 
0.82 
0.95 
30 
55 
21 
14 
20 
19 
13 
13 
9 
Akt2 125(100-185) 120(98-165) 0.551 0.81 61 22 13 
Akt3 50(0-100) 60(0-95) 0.619 0.84 48 20 30 
pAkt473m 
pAkt473c 
pAkt473n 
40(0-90) 
88(54-110) 
0(0-25) 
33(0-90) 
80(40-105) 
0(0-35) 
0.988 
0.671 
0.465 
0.90 
0.89 
0.93 
58 
49 
40 
22 
25 
15 
23 
23 
18 
pAR210n 35(0-85) 103(50-169) <0.0001 0.93 52 8 42 
mTORm 
mTORc 
0(0-20) 
43(15-87) 
0(0-10) 
40(10-62) 
0.134 
0.123 
0.92 
0.83 
47 
31 
10 
35 
3 
23 
pmTOR2448m 
pmTOR2448c 
pmTOR2448n 
0(0-22) 
61(20-100) 
0(0-10) 
0(0-15) 
40(8-70) 
0(0-0) 
0.330 
0.044 
0.575 
0.95 
0.91 
0.90 
33 
45 
19 
14 
33 
3 
8 
23 
6 
Table 1 shows the median histoscore and interquartile range (IQR) for hormone 
sensitive tumours (HSPC) and hormone refractory tumours (HRPC) and the p value of 
HSPC histoscores compared to HRPC histoscores using a Wilcoxon sign rank test.  
The median histoscore was the cut off histoscore used to select for the separate 
subgroups when defining high and low expressers. The interclass correlation 
coefficient (ICCC) which measures consistence between observers for each protein is 
consistently higher than 0.7 which is classed as excellent.  The mean difference in 
observer scores plus 2 standard deviations is also shown as the number of histoscore 
units, the is the cut-off in histoscore units used to select for the separate subgroups ie 
defined as a change in protein expression.  The percentage of tumours that were 
defined as having a fall or rise in protein expression (calculated using the number of 
histoscore units that is defined as a change in expression) are also shown. m, c and n 
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relates to protein location, m = membrane, c= cytoplasm and n = nucleus. P before a 
protein indicates that the antibody detects phosphorylated protein and the number 
following the protein represents the site of phosphorylation. 
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Table 2 Histoscores of pAkt and PI3K and comparison of staining intensity between 
patients with or without an increase in pAR210 expression. 
Group 
1    
Group 
2    
HS HS HR HR HS HS HR HR 
pAkt PI3K pAkt PI3K  pAkt PI3K pAkt PI3K  
0 80 0 70 0 30 110 95 
0 100 105 90 70 110 . 180 
90 160 0 60 50 80 . 105 
0 260 0 100 55 50 100 40 
.  .  105 105 . 160 
130 140 55 60 90 105 180 80 
90 20 125 90 0 130 40 90 
  120 160 25 30 140 100 
50 15 . 100 75 190 2.5 280 
130 70 105 0 110 200 55 35 
50 53.75 60 100 85 25 150 10 
110 200 0 132.5 100 40 5 180 
.  .  100 80 117.5 130 
135 130 40 140 80 25 90 105 
20 100 102.5 170 95 140 0 62.5 
130 105 50 120 97.5 100 75 90 
. 100 . 30 72.5 115 105 100 
100 0 5 50 0 0 110 70 
110 180 80 195 100 0 .  
100 100 20 200 75 110 120 115 
100 195 100 165 65 80 185 100 
162.5 190 90 100 0 15 90 100 
180 210 100 160 .  .  
. 90 . 120 137.5 170 35 105 
165 0 40 100 0 90 75 75 
60 40 5 25 . 200 . 137.5 
85 190 80 0 160 200 135 150 
25 115 100 100 125 170 0 190 
90 100 155 80 220 200 0 150 
35 100 70 25 120 120 . 160 
70 120 40 100 72.5 100 100 80 
85  60  75 40 130 0 
. 200 . 100 120 80 150 0 
90 100 60 100         
 
 23 
Table 2 shows the histoscore for cytoplasmic phosphorylated Akt and PI3K in 
hormone sensitive tumours (HS) and hormone refractory tumours (HR).  Group 1 
represents those patients with no increase in phosphorylated AR expression and group 
2 represents those patients with an increase in phosphorylated AR expression in the 
transition from hormone sensitive to hormone refractory disease. 
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Figure Legends 
Figure 1a shows the actual increase in histoscore units of the 42% of patients whose 
tumours exhibited an increase in pAR210 expression in the transition from hormone 
sensitive to hormone refractory disease.   
Figure 1b and 1c These images are of an actual pair of hormone sensitive and 
hormone refractory tumours whose expression increased by 150 histoscore units.  
Brown nuclear staining denotes pAR210 expression.  Magnification x400. 
Figure 1d.  These images show examples of a negative control, a tumour that was 
score with a histoscore in the range of 1-100, 101-200 or 201-300. 
Figure 2a.  Kaplan Meier plot demonstrates that those patients whose hormone 
refractory tumour has high pAR210 nuclear expression (broken line) have shorter time 
to disease specific death from time of biochemical relapse than those patients whose 
hormone refractory tumour has low pAR210 nuclear expression (solid line)(p=0.003). 
Figure 2b.  Kaplan Meier plot demonstrates that those patients whose hormone 
refractory tumour has high pAR210 nuclear expression (broken line) have shorter 
disease specific survival than those patients whose hormone refractory tumour has 
low pAR210 nuclear expression (solid line)(p=0.014).  
Figure 3a Kaplan Meier plot demonstrates that those patients whose tumours exhibit a 
rise in PI3K expression (broken line) relapse quicker than those patients whose 
tumours exhibit no change or a fall in PI3K expression (solid line).  
Figure 3b Kaplan Meier plot demonstrates that those patients whose tumours exhibit a 
rise in pAR210 expression (broken line) have shorter time to disease specific death 
from time of biochemical relapse than those patients whose tumours exhibit no 
change or a fall in pAR210 expression (solid line). whose tumours had an increase in 
pAR210 expression.   
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Figure 3c Kaplan Meier plot demonstrates that those patients whose tumours exhibit a 
rise in pAkt473 cytoplasmic expression (broken line) have shorter time to disease 
specific death than those patients whose tumours exhibit no change or a fall in pAkt473 
expression (solid line).  
Figure 3d Kaplan Meier plot demonstrates that those patients whose tumours exhibit a 
rise in pAR210 expression (broken line) have shorter time to disease specific death 
than those patients whose tumours exhibit no change or a fall in pAR210 expression 
(solid line).   
Figure 4 Scatter plots of phosphorylated Akt 473 histoscore compared to 
phosphorylated AR 210 histoscore, figure 4a is in the hormone sensitive tissue and no 
significant correlation was observed (p=0.061, correlation coefficient 0.251), however 
figure 4b is in the hormone refractory tissue where a significant correlation was 
observed (p<0.001 and correlation coefficient 0.711). 
Figure 5 A simplified cartoon of the PI3K/Akt pathway; the p values and correlation 
coefficients (rs) represent those found when protein expression/activation were 
correlated in hormone refractory prostate cancer tissue specimens. 
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